SCHEMBL1664148

SCHEMBL1664148

CC(C)c1nc2cc(O)ccc2c(=O)n1CCO

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.54
HDAC1 Q13547 2/20 0.46
HDAC6 Q9UBN7 1/20 0.46
ESR1 P03372 3/20 0.43
ESR2 Q92731 2/20 0.43
AKR1B1 P15121 1/20 0.39
TSHR P16473 1/20 0.39
GFER P55789 1/20 0.38
PDE5A O76074 1/20 0.38
GAA P10253 1/20 0.38
CASR P41180 2/20 0.37
MAPT P10636 2/20 0.37
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MCOLN3 Q8TDD5 1/20 0.37
ALDH1A1 P00352 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1663421 0.90 TRPV1 (0.54) TRPV1HDAC1HDAC6ESR1ESR2
SCHEMBL1664240 0.88 TRPV1 (0.48) TRPV1HDAC1HDAC6ESR1ESR2
SCHEMBL1663609 0.86 TRPV1 (0.51) TRPV1HDAC1HDAC6ESR1ESR2
SCHEMBL1663283 0.85 TRPV1 (0.50) TRPV1HDAC1HDAC6ESR1ESR2
SCHEMBL1663306 0.81 TRPV1 (0.51) TRPV1HDAC1HDAC6ESR1ESR2
SCHEMBL1663405 0.81 TRPV1 (0.46) TRPV1HDAC1HDAC6ESR1ESR2
SCHEMBL1663914 0.80 TRPV1 (0.50) TRPV1HDAC1HDAC6ESR1ESR2
SCHEMBL1663625 0.80 TRPV1 (0.50) TRPV1HDAC1HDAC6ESR1ESR2
SCHEMBL1663935 0.79 TRPV1 (0.49) TRPV1HDAC1HDAC6ESR1ESR2
SCHEMBL1663509 0.78 TRPV1 (0.48) TRPV1HDAC1HDAC6ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
CN-101356160-A Trisubstituted quinazolinone derivatives as vanilloid antagonists JANSSEN PHARMACEUTICA NV (CH) 2009-01-28 CN disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 TRPV1 1/4885HDAC1 999/4885HDAC6 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.